MA46778B1 - Composition intranasale comprenant de la bétahistine - Google Patents
Composition intranasale comprenant de la bétahistineInfo
- Publication number
- MA46778B1 MA46778B1 MA46778A MA46778A MA46778B1 MA 46778 B1 MA46778 B1 MA 46778B1 MA 46778 A MA46778 A MA 46778A MA 46778 A MA46778 A MA 46778A MA 46778 B1 MA46778 B1 MA 46778B1
- Authority
- MA
- Morocco
- Prior art keywords
- betahistine
- intranasal composition
- intranasal
- otological
- composition
- Prior art date
Links
- UUQMNUMQCIQDMZ-UHFFFAOYSA-N betahistine Chemical compound CNCCC1=CC=CC=N1 UUQMNUMQCIQDMZ-UHFFFAOYSA-N 0.000 title abstract 2
- 229960004536 betahistine Drugs 0.000 title abstract 2
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Otolaryngology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Dispersion Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La présente invention concerne une composition pharmaceutique comprenant en tant que substance active de la bétahistine ou un sel pharmaceutiquement acceptable de celle-ci, destinée à être utilisée dans le traitement de troubles otologiques ou neurologiques chez un sujet humain par application intranasale.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762453931P | 2017-02-02 | 2017-02-02 | |
PCT/EP2018/052695 WO2018141922A1 (fr) | 2017-02-02 | 2018-02-02 | Composition intranasale comprenant de la bétahistine |
Publications (2)
Publication Number | Publication Date |
---|---|
MA46778A1 MA46778A1 (fr) | 2021-04-30 |
MA46778B1 true MA46778B1 (fr) | 2022-08-31 |
Family
ID=61187302
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA46778A MA46778B1 (fr) | 2017-02-02 | 2018-02-02 | Composition intranasale comprenant de la bétahistine |
Country Status (34)
Country | Link |
---|---|
US (2) | US10456386B2 (fr) |
EP (2) | EP3474850B1 (fr) |
JP (3) | JP2020506930A (fr) |
KR (1) | KR102653545B1 (fr) |
CN (2) | CN110418643A (fr) |
AR (1) | AR111699A1 (fr) |
AU (1) | AU2018216970B2 (fr) |
BR (1) | BR112019015687A2 (fr) |
CA (1) | CA3051725A1 (fr) |
CL (1) | CL2019002145A1 (fr) |
CO (1) | CO2019008657A2 (fr) |
DK (2) | DK3698791T3 (fr) |
EA (1) | EA201991817A1 (fr) |
ES (2) | ES2807798T3 (fr) |
FI (1) | FI3698791T3 (fr) |
HR (2) | HRP20231706T1 (fr) |
HU (2) | HUE065336T2 (fr) |
IL (1) | IL268353B2 (fr) |
LT (2) | LT3474850T (fr) |
MA (1) | MA46778B1 (fr) |
MX (1) | MX2019008961A (fr) |
MY (1) | MY196333A (fr) |
NZ (1) | NZ755931A (fr) |
PH (1) | PH12019501785A1 (fr) |
PL (2) | PL3474850T3 (fr) |
PT (2) | PT3474850T (fr) |
RS (2) | RS65099B1 (fr) |
SA (1) | SA519402324B1 (fr) |
SG (1) | SG11201906980YA (fr) |
SI (2) | SI3474850T1 (fr) |
TN (1) | TN2019000220A1 (fr) |
TW (1) | TWI760429B (fr) |
WO (1) | WO2018141922A1 (fr) |
ZA (1) | ZA201904955B (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018170532A1 (fr) * | 2017-03-22 | 2018-09-27 | Franz, Lilian Ann | Procéde de traitement |
CN115551479A (zh) * | 2020-04-14 | 2022-12-30 | 葛兰素史克消费者健康控股(美国)有限责任公司 | 具有保湿益处的鼻喷雾制剂 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2397840B1 (fr) | 1977-07-22 | 1981-03-20 | Cherqui Jean | |
IT1229237B (it) * | 1989-05-08 | 1991-07-26 | Prodotti Formenti | Sali di (2-(piridil)etil) metilammina |
JPH03287535A (ja) * | 1990-03-31 | 1991-12-18 | Bairon Boeki Kk | プラノプロフェン水溶液 |
JP3203056B2 (ja) * | 1992-08-13 | 2001-08-27 | 株式会社ティ・ティ・エス技術研究所 | メシル酸ベタヒスチンの経皮吸収製剤用組成物および経皮吸収製剤 |
US5897858A (en) * | 1994-02-03 | 1999-04-27 | Schering-Plough Healthcare Products, Inc. | Nasal spray compositions exhibiting increased retention in the nasal cavity |
JPH10139667A (ja) * | 1996-11-15 | 1998-05-26 | Yoshitomi Pharmaceut Ind Ltd | 水性液剤 |
US7090830B2 (en) | 2001-05-24 | 2006-08-15 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
EP1392262A1 (fr) | 2001-05-24 | 2004-03-03 | Alexza Molecular Delivery Corporation | Administration d'esters medicamenteux par inhalation |
JP3555598B2 (ja) | 2001-06-27 | 2004-08-18 | 株式会社村田製作所 | 積層型インダクタ |
JP2004196676A (ja) * | 2002-12-16 | 2004-07-15 | Rohto Pharmaceut Co Ltd | 点鼻剤 |
JP4733333B2 (ja) * | 2002-12-26 | 2011-07-27 | ライオン株式会社 | 点鼻剤又は洗鼻剤 |
PT1530965E (pt) | 2003-11-11 | 2006-05-31 | Udo Mattern | Sistema de administracao de libertacao controlada de hormonas sexuais para aplicacao nasal |
AU2006202950A1 (en) * | 2004-04-22 | 2006-10-19 | Mor Research Applications Ltd. | Methods and Compositions for Weight Management |
JP2007533733A (ja) | 2004-04-22 | 2007-11-22 | モル リサーチ アプリケーションズ リミテッド | 食物摂取管理の方法 |
US7728015B2 (en) * | 2004-04-22 | 2010-06-01 | Mor Research Applications Ltd. | Compositions for weight management |
EP2457580A1 (fr) | 2004-08-25 | 2012-05-30 | The UAB Research Foundation | Activateurs de l'absorption pour l'administration de médicaments |
US20060046962A1 (en) | 2004-08-25 | 2006-03-02 | Aegis Therapeutics Llc | Absorption enhancers for drug administration |
JP2009504767A (ja) * | 2005-08-17 | 2009-02-05 | フレミング・アンド・カンパニー・ファーマシューティカルズ | ビタミンb12鼻用スプレーおよび使用方法 |
WO2007076140A2 (fr) * | 2005-12-23 | 2007-07-05 | University Of Cincinnati | Procedes de traitement employant des antagonistes d’histamine h3 y compris de la betahistine |
US8242148B2 (en) * | 2005-12-23 | 2012-08-14 | Nelson Erik B | Treatment methods employing histamine H3 receptor antagonists, including betahistine |
US20080066739A1 (en) | 2006-09-20 | 2008-03-20 | Lemahieu Edward | Methods and systems of delivering medication via inhalation |
CN101951886A (zh) * | 2007-12-21 | 2011-01-19 | 先灵-普劳健康护理产品公司 | 增强羟甲唑啉的光稳定性 |
KR20130097813A (ko) * | 2008-04-21 | 2013-09-03 | 오토노미, 인코포레이티드 | 귀 질환 및 병태를 치료하기 위한 귀 조제물 |
PT2293794E (pt) * | 2008-05-27 | 2013-07-10 | Univ Melbourne | Métodos de tratamento de mamíferos com disfunções da trompa de eustáquio |
CN102216257B (zh) * | 2008-10-08 | 2015-11-25 | 凯飞药业公司 | Gaba偶联物及其使用方法 |
AU2015327762C1 (en) * | 2014-10-03 | 2020-10-22 | Lachesis Biosciences Limited | Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders |
-
2018
- 2018-02-02 HR HRP20231706TT patent/HRP20231706T1/hr unknown
- 2018-02-02 SI SI201830082T patent/SI3474850T1/sl unknown
- 2018-02-02 FI FIEP20170448.3T patent/FI3698791T3/fi active
- 2018-02-02 PT PT187037494T patent/PT3474850T/pt unknown
- 2018-02-02 EP EP18703749.4A patent/EP3474850B1/fr active Active
- 2018-02-02 LT LTEP18703749.4T patent/LT3474850T/lt unknown
- 2018-02-02 BR BR112019015687A patent/BR112019015687A2/pt unknown
- 2018-02-02 AR ARP180100254A patent/AR111699A1/es unknown
- 2018-02-02 PL PL18703749T patent/PL3474850T3/pl unknown
- 2018-02-02 EP EP20170448.3A patent/EP3698791B1/fr active Active
- 2018-02-02 AU AU2018216970A patent/AU2018216970B2/en active Active
- 2018-02-02 CN CN201880017726.2A patent/CN110418643A/zh active Pending
- 2018-02-02 CN CN202410176958.XA patent/CN118356397A/zh active Pending
- 2018-02-02 ES ES18703749T patent/ES2807798T3/es active Active
- 2018-02-02 NZ NZ755931A patent/NZ755931A/en unknown
- 2018-02-02 US US15/887,388 patent/US10456386B2/en active Active
- 2018-02-02 RS RS20240022A patent/RS65099B1/sr unknown
- 2018-02-02 JP JP2019541717A patent/JP2020506930A/ja active Pending
- 2018-02-02 LT LTEP20170448.3T patent/LT3698791T/lt unknown
- 2018-02-02 IL IL268353A patent/IL268353B2/en unknown
- 2018-02-02 MX MX2019008961A patent/MX2019008961A/es unknown
- 2018-02-02 ES ES20170448T patent/ES2969301T3/es active Active
- 2018-02-02 SG SG11201906980YA patent/SG11201906980YA/en unknown
- 2018-02-02 KR KR1020197025622A patent/KR102653545B1/ko active IP Right Grant
- 2018-02-02 TW TW107103800A patent/TWI760429B/zh active
- 2018-02-02 EA EA201991817A patent/EA201991817A1/ru unknown
- 2018-02-02 SI SI201831043T patent/SI3698791T1/sl unknown
- 2018-02-02 DK DK20170448.3T patent/DK3698791T3/da active
- 2018-02-02 WO PCT/EP2018/052695 patent/WO2018141922A1/fr unknown
- 2018-02-02 TN TNP/2019/000220A patent/TN2019000220A1/en unknown
- 2018-02-02 PL PL20170448.3T patent/PL3698791T3/pl unknown
- 2018-02-02 MY MYPI2019004366A patent/MY196333A/en unknown
- 2018-02-02 HU HUE20170448A patent/HUE065336T2/hu unknown
- 2018-02-02 PT PT201704483T patent/PT3698791T/pt unknown
- 2018-02-02 HU HUE18703749A patent/HUE050829T2/hu unknown
- 2018-02-02 MA MA46778A patent/MA46778B1/fr unknown
- 2018-02-02 CA CA3051725A patent/CA3051725A1/fr active Pending
- 2018-02-02 RS RS20200851A patent/RS60554B1/sr unknown
- 2018-02-02 DK DK18703749.4T patent/DK3474850T3/da active
-
2019
- 2019-07-26 SA SA519402324A patent/SA519402324B1/ar unknown
- 2019-07-29 ZA ZA2019/04955A patent/ZA201904955B/en unknown
- 2019-07-30 CL CL2019002145A patent/CL2019002145A1/es unknown
- 2019-08-05 PH PH12019501785A patent/PH12019501785A1/en unknown
- 2019-08-09 CO CONC2019/0008657A patent/CO2019008657A2/es unknown
- 2019-09-13 US US16/570,156 patent/US20200022963A1/en not_active Abandoned
-
2020
- 2020-07-20 HR HRP20201137TT patent/HRP20201137T1/hr unknown
-
2022
- 2022-02-08 JP JP2022017792A patent/JP2022051872A/ja not_active Withdrawn
-
2024
- 2024-01-04 JP JP2024000158A patent/JP2024019731A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY38425A (es) | Procesos novedosos para preparar n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1- isopropil-1h-pirazol-3-sulfonamida y sales de éste | |
MA39725B1 (fr) | Compositions pharmaceutiques de composés thérapeutiquement actifs | |
BR112019025049A2 (pt) | Anéis 6- 5 fundidos como inibidores de c5a | |
MA43828A (fr) | Agents thérapeutiques pour maladies neurodégénératives | |
MA39359A1 (fr) | Composés d'isoindolinone utilisés comme modulateurs de gpr119 pour le traitement du diabète, de l'obésité et de troubles associés | |
BR112019025230A2 (pt) | Anéis 5-5 fundidos como inibidores de c5a | |
MA46665B1 (fr) | Composés de tyrosine tyrosine de peptide cyclique couplés à un anticorps en tant que modulateurs des récepteurs du neuropeptide y | |
MA35513B1 (fr) | Compositions pharmaceutiques comprenant 40 - o - ( 2 - hydroxy) éthyl - rapamycine | |
BR112015019412A2 (pt) | inibidores de bace1 | |
MA39346B1 (fr) | Hétérocycles substitués liés par fusion en tant que modulateurs gpr119 pour le traitement du diabète, de l'obésité, de la dyslipidémie et de troubles associés | |
CN107406464A8 (zh) | 精氨酸酶抑制剂及其治疗用途 | |
MA50406B1 (fr) | Inhibiteurs pyrazole de magl | |
BR112018013084A2 (pt) | tratamentos de combinação compreendendo a administração de imidazopirazinonas | |
MX2020009235A (es) | Formulacion oftalmica. | |
MY189740A (en) | Butylphthalide-telmisartan heterocomplex, preparation method and application thereof | |
MA43876B1 (fr) | Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale | |
EA201590066A1 (ru) | Дифторгексагидроциклопентаоксазинилы и дифторгексагидробензоксазинилы в качестве ингибиторов бета-секретазы 1 | |
MA39447B1 (fr) | Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine | |
MA46778B1 (fr) | Composition intranasale comprenant de la bétahistine | |
EA201991490A1 (ru) | Ароматические амиды карбоновых кислот в качестве антагонистов рецепторов брадикинина в1 | |
EA202190316A1 (ru) | Конденсированное производное лактама | |
BR112018073419A2 (pt) | combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica | |
EA201990550A1 (ru) | Офтальмологический препарат, включающий азоловое соединение | |
CL2017002229A1 (es) | Inhibidores de bace1. | |
MA39448B1 (fr) | (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical |